Overview
NICE is unable to make a recommendation on melphalan (Phelinun) for treating haematological diseases before allogeneic haematopoietic stem cell transplant because ADIENNE did not provide an evidence submission.
Last reviewed: 14 September 2022
Next review: We will review this decision if the company decides to make a submission.